Repligen Corporation

RGEN Healthcare Medical Instruments & Supplies

Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024.

Revenue
+10.9%
EPS
−351.9%
Free cash flow
−11.5%
Total debt
+3.28%

Quarter to September 2026, against a year earlier

173.84 5.36 +3.18%
Market cap
$10.8B
P/E
0.0×
Fwd P/E
−615×
Dividend yield
—
F-score
6/9
Altman Z
7.49
Beneish M
−2.52
Dividend safety
n/a

Repligen Corporation 8-K filed Jul 22, 2026

Period ended Jul 21, 2026 · Filed · accepted 8:56 AM ET · Document on sec.gov · Filing index

1.01 Entry into a material definitive agreement; 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov The press release